Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
Die vorliegende Erfindung betrifft die Verwendung von Agenzien, die die Expression und/oder Aktivität der Proteinkinase C-alpha (PKC-alpha) vermindern oder hemmen, zur Behandlung und/oder Prävention von koronarer Herzerkrankung, Herzinfarkt, peripherer Verschlusskrankheit, Schlaganfall, mit Proteinu...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Patent |
| Sprache: | ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | MENNE, JAN HALLER, HERRMANN |
| description | Die vorliegende Erfindung betrifft die Verwendung von Agenzien, die die Expression und/oder Aktivität der Proteinkinase C-alpha (PKC-alpha) vermindern oder hemmen, zur Behandlung und/oder Prävention von koronarer Herzerkrankung, Herzinfarkt, peripherer Verschlusskrankheit, Schlaganfall, mit Proteinurie einhergehenden Nierenerkrankungen, diabetischen Spätschäden und/oder kardiovaskulären Komplikationen bei Patienten mit Diabetes mellitus, kardiovaskulären Komplikationen bei Patienten mit Hypertonus und kardiovaskulären Komplikationen bei Patienten mit Hypercholesterinämie.
Using an agent (A) that reduces or inhibits expression and/or activity of protein kinase Calpha (PKCa) for treatment and/or prevention of vascular and cardiovascular diseases, kidney diseases associated with proteinuria, long-term damage caused by diabetes and/or cardiovascular complications associated with diabetes mellitus, hypertension and/or hypercholesterolemia, is new. ACTIVITY : Cardiant; Vasotropic; Nephrotropic; Antidiabetic; Hypotensive; Antilipemic; Cerebroprotective; Ophthalmological; Neuroprotective. No biological data given. MECHANISM OF ACTION : Inhibiting expression and/or activity of PKCa, resulting in reduced expression of vascular endothelial growth factor (and of its receptor) in the kidney. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_DE10244453A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DE10244453A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_DE10244453A13</originalsourceid><addsrcrecordid>eNrjZHDwSM3NLc1LV0hJLVIIKMovSc3My87MSyxOVXDWTcwpyEhUqCotUnBKzUjMS8kBKSzLz1PwLkrMy85IzSxJzeNhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfEuroYGRiYmJqbGjobGxKgBAKHzMOU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten</title><source>esp@cenet</source><creator>MENNE, JAN ; HALLER, HERRMANN</creator><creatorcontrib>MENNE, JAN ; HALLER, HERRMANN</creatorcontrib><description>Die vorliegende Erfindung betrifft die Verwendung von Agenzien, die die Expression und/oder Aktivität der Proteinkinase C-alpha (PKC-alpha) vermindern oder hemmen, zur Behandlung und/oder Prävention von koronarer Herzerkrankung, Herzinfarkt, peripherer Verschlusskrankheit, Schlaganfall, mit Proteinurie einhergehenden Nierenerkrankungen, diabetischen Spätschäden und/oder kardiovaskulären Komplikationen bei Patienten mit Diabetes mellitus, kardiovaskulären Komplikationen bei Patienten mit Hypertonus und kardiovaskulären Komplikationen bei Patienten mit Hypercholesterinämie.
Using an agent (A) that reduces or inhibits expression and/or activity of protein kinase Calpha (PKCa) for treatment and/or prevention of vascular and cardiovascular diseases, kidney diseases associated with proteinuria, long-term damage caused by diabetes and/or cardiovascular complications associated with diabetes mellitus, hypertension and/or hypercholesterolemia, is new. ACTIVITY : Cardiant; Vasotropic; Nephrotropic; Antidiabetic; Hypotensive; Antilipemic; Cerebroprotective; Ophthalmological; Neuroprotective. No biological data given. MECHANISM OF ACTION : Inhibiting expression and/or activity of PKCa, resulting in reduced expression of vascular endothelial growth factor (and of its receptor) in the kidney.</description><edition>7</edition><language>ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2004</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20040401&DB=EPODOC&CC=DE&NR=10244453A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20040401&DB=EPODOC&CC=DE&NR=10244453A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MENNE, JAN</creatorcontrib><creatorcontrib>HALLER, HERRMANN</creatorcontrib><title>Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten</title><description>Die vorliegende Erfindung betrifft die Verwendung von Agenzien, die die Expression und/oder Aktivität der Proteinkinase C-alpha (PKC-alpha) vermindern oder hemmen, zur Behandlung und/oder Prävention von koronarer Herzerkrankung, Herzinfarkt, peripherer Verschlusskrankheit, Schlaganfall, mit Proteinurie einhergehenden Nierenerkrankungen, diabetischen Spätschäden und/oder kardiovaskulären Komplikationen bei Patienten mit Diabetes mellitus, kardiovaskulären Komplikationen bei Patienten mit Hypertonus und kardiovaskulären Komplikationen bei Patienten mit Hypercholesterinämie.
Using an agent (A) that reduces or inhibits expression and/or activity of protein kinase Calpha (PKCa) for treatment and/or prevention of vascular and cardiovascular diseases, kidney diseases associated with proteinuria, long-term damage caused by diabetes and/or cardiovascular complications associated with diabetes mellitus, hypertension and/or hypercholesterolemia, is new. ACTIVITY : Cardiant; Vasotropic; Nephrotropic; Antidiabetic; Hypotensive; Antilipemic; Cerebroprotective; Ophthalmological; Neuroprotective. No biological data given. MECHANISM OF ACTION : Inhibiting expression and/or activity of PKCa, resulting in reduced expression of vascular endothelial growth factor (and of its receptor) in the kidney.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2004</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHDwSM3NLc1LV0hJLVIIKMovSc3My87MSyxOVXDWTcwpyEhUqCotUnBKzUjMS8kBKSzLz1PwLkrMy85IzSxJzeNhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfEuroYGRiYmJqbGjobGxKgBAKHzMOU</recordid><startdate>20040401</startdate><enddate>20040401</enddate><creator>MENNE, JAN</creator><creator>HALLER, HERRMANN</creator><scope>EVB</scope></search><sort><creationdate>20040401</creationdate><title>Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten</title><author>MENNE, JAN ; HALLER, HERRMANN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_DE10244453A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>ger</language><creationdate>2004</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>MENNE, JAN</creatorcontrib><creatorcontrib>HALLER, HERRMANN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MENNE, JAN</au><au>HALLER, HERRMANN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten</title><date>2004-04-01</date><risdate>2004</risdate><abstract>Die vorliegende Erfindung betrifft die Verwendung von Agenzien, die die Expression und/oder Aktivität der Proteinkinase C-alpha (PKC-alpha) vermindern oder hemmen, zur Behandlung und/oder Prävention von koronarer Herzerkrankung, Herzinfarkt, peripherer Verschlusskrankheit, Schlaganfall, mit Proteinurie einhergehenden Nierenerkrankungen, diabetischen Spätschäden und/oder kardiovaskulären Komplikationen bei Patienten mit Diabetes mellitus, kardiovaskulären Komplikationen bei Patienten mit Hypertonus und kardiovaskulären Komplikationen bei Patienten mit Hypercholesterinämie.
Using an agent (A) that reduces or inhibits expression and/or activity of protein kinase Calpha (PKCa) for treatment and/or prevention of vascular and cardiovascular diseases, kidney diseases associated with proteinuria, long-term damage caused by diabetes and/or cardiovascular complications associated with diabetes mellitus, hypertension and/or hypercholesterolemia, is new. ACTIVITY : Cardiant; Vasotropic; Nephrotropic; Antidiabetic; Hypotensive; Antilipemic; Cerebroprotective; Ophthalmological; Neuroprotective. No biological data given. MECHANISM OF ACTION : Inhibiting expression and/or activity of PKCa, resulting in reduced expression of vascular endothelial growth factor (and of its receptor) in the kidney.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | ger |
| recordid | cdi_epo_espacenet_DE10244453A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T15%3A16%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MENNE,%20JAN&rft.date=2004-04-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EDE10244453A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |